How to buy Karuna Therapeutics stock (KRTX)

Karuna Therapeutics is a biotechnology business based in the US. Karuna Therapeutics shares (KRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Karuna Therapeutics employs 339 staff and has a trailing 12-month revenue of around $654,000.

Our top picks for where to buy Karuna Therapeutics stock

Buy Karuna Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Karuna Therapeutics stock price (NASDAQ: KRTX)

Use our graph to track the performance of KRTX stocks over time.

Karuna Therapeutics shares at a glance

• Key figures

Information last updated 2024-05-19.

52-week range	$296.06 - $329.99
50-day moving average more info button	$317.71
200-day moving average more info button	$230.08
Wall St. target price	$324.17
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-11.74

Is it a good time to buy Karuna Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karuna Therapeutics financials

Revenue TTM	$654,000
Gross profit TTM	$10.6 million
Return on assets TTM	-24.71%
Return on equity TTM	-36.44%
Profit margin	0%
Book value	$32.94
Market Capitalization more info button	$12.6 billion

TTM: trailing 12 months

Karuna Therapeutics share dividends

We're not expecting Karuna Therapeutics to pay a dividend over the next 12 months.

Karuna Therapeutics share price volatility

Over the last 12 months, Karuna Therapeutics's shares have ranged in value from as little as $296.06 up to $329.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karuna Therapeutics's is 1.149. This would suggest that Karuna Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Karuna Therapeutics overview

Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co. , Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc.

Frequently asked questions

What percentage of Karuna Therapeutics is owned by insiders or institutions?
Currently 4.986% of Karuna Therapeutics shares are held by insiders and 86.324% by institutions. How many people work for Karuna Therapeutics?
Latest data suggests 339 work at Karuna Therapeutics. When does the fiscal year end for Karuna Therapeutics?
Karuna Therapeutics's fiscal year ends in December. Where is Karuna Therapeutics based?
Karuna Therapeutics's address is: 99 High Street, Boston, MA, United States, 02110 What is Karuna Therapeutics's ISIN number?
Karuna Therapeutics's international securities identification number is: US48576A1007 What is Karuna Therapeutics's CUSIP number?
Karuna Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576A100